Notably, PX-478 alone and the combination of PX-478 with neratinib showed significant tumor growth inhibition (p < 0.05) in both two trastuzumab-exposed HR−/HER2+ PDX models compared with controls (Figure 4 and Figure 5B,C). Here, ERBB2 is linked to neoplasm.